We used systems-level analyses to direct our functional studies and found a key mechanism integrating αVβ6 integrin and HER2 functions, which drives breast cancer invasion and is dysregulated by trastuzumab resistance (Fig. 7). Here, ERBB2 is linked to breast carcinoma.